Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06464068 |
Title | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC) |
Acronym | DURVASCC |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Gruppo Oncologico Italiano di Ricerca Clinica |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | ITA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
AUSL-IRCCS of Reggio Emilia | RECRUITING | Reggio Emilia | 42123 | Italy | Details |